These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22023476)

  • 1. Building mosaics of therapeutic plasmid gene vectors.
    Tolmachov OE
    Curr Gene Ther; 2011 Dec; 11(6):466-78. PubMed ID: 22023476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of plasmid-mediated expression of transgenes in human mesenchymal stem cells depends primarily on CpG levels of both vector and transgene.
    Bruter AV; Kandarakov OF; Belyavsky AV
    J Gene Med; 2018 Feb; 20(2-3):e3009. PubMed ID: 29424052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tightly-wound miniknot vectors for gene therapy: a potential improvement over supercoiled minicircle DNA.
    Tolmachov OE
    Med Hypotheses; 2010 Apr; 74(4):702-4. PubMed ID: 19914006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG methylation of a plasmid vector results in extended transgene product expression by circumventing induction of immune responses.
    Reyes-Sandoval A; Ertl HC
    Mol Ther; 2004 Feb; 9(2):249-61. PubMed ID: 14759809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naked plasmid DNA for gene therapy.
    Shimamura M; Morishita R
    Curr Gene Ther; 2011 Dec; 11(6):433. PubMed ID: 22023468
    [No Abstract]   [Full Text] [Related]  

  • 6. [Maintenance of Plasmid Expression in vivo Depends Primarily on the CpG Contents of the Vector and Transgene].
    Bruter AV; Kalashnikova MV; Prytyko AP; Belyavsky AV
    Mol Biol (Mosk); 2020; 54(3):487-496. PubMed ID: 32492013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Optimization of in-vivo gene transfer through regulating biological response to vectors].
    Nishikawa M
    Yakugaku Zasshi; 2006 Nov; 126(11):1029-37. PubMed ID: 17077609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-focusing therapeutic gene delivery with intelligent gene vector swarms: intra-swarm signalling through receptor transgene expression in targeted cells.
    Tolmachov OE
    Artif Intell Med; 2015 Jan; 63(1):1-6. PubMed ID: 25547266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation.
    Chen ZY; Riu E; He CY; Xu H; Kay MA
    Mol Ther; 2008 Mar; 16(3):548-56. PubMed ID: 18253155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of safe and effective nonviral gene therapy by eliminating CpG motifs from plasmid DNA vector.
    Takahashi Y; Nishikawa M; Takakura Y
    Front Biosci (Schol Ed); 2012 Jan; 4(1):133-41. PubMed ID: 22202048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of nonviral gene therapy by Epstein-Barr virus (EBV)-based plasmid vectors.
    Mazda O
    Curr Gene Ther; 2002 Sep; 2(3):379-92. PubMed ID: 12189722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides.
    Hodges BL; Taylor KM; Joseph MF; Bourgeois SA; Scheule RK
    Mol Ther; 2004 Aug; 10(2):269-78. PubMed ID: 15294174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional plasmid DNAs with a CpG-containing backbone achieve durable transgene expression in mouse liver.
    Suzuki T; Wakao Y; Goda T; Kamiya H
    J Gene Med; 2020 Jan; 22(1):e3138. PubMed ID: 31696985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PhiC31 integrase mediates integration in cultured synovial cells and enhances gene expression in rabbit joints.
    Keravala A; Portlock JL; Nash JA; Vitrant DG; Robbins PD; Calos MP
    J Gene Med; 2006 Aug; 8(8):1008-17. PubMed ID: 16779871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing plasmid vectors.
    Tolmachov O
    Methods Mol Biol; 2009; 542():117-29. PubMed ID: 19565899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of high quality minicircle DNA for in vitro and in vivo gene transfer.
    Kobelt D; Schleef M; Schmeer M; Aumann J; Schlag PM; Walther W
    Mol Biotechnol; 2013 Jan; 53(1):80-9. PubMed ID: 22467123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of plasmid DNA-based non-viral gene medicine.
    Nishikawa M; Takakura Y; Hashida M
    Adv Genet; 2005; 53():47-68. PubMed ID: 16240990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased maintenance and persistence of transgenes by excision of expression cassettes from plasmid sequences in vivo.
    Riu E; Grimm D; Huang Z; Kay MA
    Hum Gene Ther; 2005 May; 16(5):558-70. PubMed ID: 15916481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo evaluation of intrinsic immunogenicity of reporter and insulin gene therapy plasmids.
    Ratanamart J; Huggins CG; Kirby JA; Shaw JA
    J Gene Med; 2007 Aug; 9(8):703-14. PubMed ID: 17595049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the Development and the Applications of Nonviral, Episomal Vectors for Gene Therapy.
    Mulia GE; Picanço-Castro V; Stavrou EF; Athanassiadou A; Figueiredo ML
    Hum Gene Ther; 2021 Oct; 32(19-20):1076-1095. PubMed ID: 34348480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.